Back to search
FDAFDA · Food and drugs·Recall number D-0125-2021

Imatinib Mesylate Tablets 400 mg, Rx Only, 30-count Bottle, Manufactured by: Shilpa Medicare Limited, India, Distributed by: Armas Pharmaceuticals Inc., Manalapan, NJ 07726, NDC 72485-203-30.

Published December 16, 2020 · Recall initiated: December 8, 2020

Summary

FDA records drug Class II recall D-0125-2021, published December 16, 2020 and initiated December 8, 2020. Recalling firm: Shilpa Medicare Limited; Status: Terminated; Reported quantity: 4166 bottles; Lot: Lot #s: 7S10032A, 7S10034A, Exp. 02/28/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations

What to do

Voluntary: Firm initiated · Letter

Get an email if IMATINIB MESYLATE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
IMATINIB MESYLATE
Manufacturer
Shilpa Medicare Limited
Distributor
Nationwide in the U.S.
UPC
0372485203307
Lot
Lot #s: 7S10032A, 7S10034A, Exp. 02/28/2021
Risk classification
Class II
Area (FDA)
drug
Country
India

Related recalls

Questions about this recall

Was Imatinib Mesylate Tablets 400 mg, Rx Only, 30-count Bottle, Manufactured by: Shilpa Medicare Limited, India, Distributed by: Armas Pharmaceuticals Inc., Manalapan, NJ 07726, NDC 72485-203-30. recalled?

Yes. FDA published recall D-0125-2021 on December 16, 2020. Reported hazard: CGMP Deviations

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: IMATINIB MESYLATE. UPC: 0372485203307.